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EDITORIALS
Folic acid and birth malformations
Despite 15 years of evidence, preventable defects still occur 
With prevalences of 10-15 per 10 000 and 20 per 
10 000 live births, neural tube defects and oral clefts 
are among the most common congenital malforma-
tions. Good evidence shows that periconceptional 
supplementation with folic acid reduces the risk of 
neural tube defects.1 2 What is less clear is the effect of 
folic acid supplementation on other birth defects, such 
as cleft lip, with or without cleft palate.
In this week’s BMJ, Wilcox and colleagues3 report 
a population based case-control study from Norway, 
which shows that supplementation with folic acid in 
the periconceptional period reduces the risk of cleft lip, 
with or without cleft palate, in newborns. Supplementa-
tion with 400 µg of folic acid for three months around 
conception was associated with a 40% reduction in the 
prevalence of cleft lip, with or without cleft palate, at 
birth (adjusted odds ratio 0.61, 95% confidence inter-
val 0.39 to 0.96). Exposure data were obtained retro-
spectively one year after conception, but the reliability 
of the data was enhanced by evaluating information 
on pill bottle labels and brands. This was a large, well 
designed study that used high quality registries; this 
enabled efficient early case identification and control 
selection. The study supports findings from other recent 
studies,4 including a large meta-analysis.5
The evidence that folic acid reduces malformations 
is robust, but how much is needed and how it should 
be taken is less clear. Despite these uncertainties, 
400 µg folic acid per day has been estimated to prevent 
a large proportion of neural tube defects.1 2 Three pub-
lic health strategies for reaching this dose have been 
suggested. The first is for women to eat a diet rich in 
natural folates. However, it is difficult to reach this dose 
with diet alone, and folate in the diet has lower bio-
availability than synthetic folic acid. The second is for 
women to take supplements of folic acid in the pericon-
ceptual period. This strategy is compromised by low 
compliance and high rates of unplanned pregnancy. 
Studies have shown that although mass media cam-
paigns increased awareness up to nearly 80%, fewer 
than 50% of women followed the recommendations.6 7 
The third strategy is mandatory fortification of staple 
foods (such as wheat, corn flour, or rice). This would 
achieve coverage in a large section of the population. 
Countries differ substantially in their choices of preven-
tive strategy. 
The World Health Organization has recommended 
supplementation with 400 µg of folic acid in the peri-
conceptual period. Fortification of food is mandatory 
in an increasing number of countries (Brazil, Canada, 
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Chile, Costa Rica, Jordan, South Africa, and the United 
States). In general, however, Europe has not followed, 
despite the finding that even suboptimal fortification (for 
example, 180 µg/day in the US) greatly reduces neural 
tube defect rates.7 8 Further support for mandatory forti-
fication of food comes from a cohort study showing that 
simply recommending women planning pregnancy to 
take folic acid is not enough to substantially reduce the 
prevalence of neural tube defects at birth.9 Accumulat-
ing evidence of a protective effect of folic acid supple-
mentation on the prevalence of oral cleft defects3 10-12 
also supports the introduction of mandatory food 
fortification. However, in many European countries 
mandatory fortification has been limited by theoreti-
cal concerns. These include the potential of masking 
symptoms of vitamin B12 deficiency, interactions with 
certain drugs (antifolates),6 and other unrecognised 
adverse effects such as the risk that some women may 
have idiosyncratic reactions to folic acid even in small 
amounts (and others might need far larger doses for a 
preventive or therapeutic effect). But mandatory folic 
acid fortification to achieve around 180 µg/day on 
average and 1000 µg/day at maximum holds little risk 
of complications.6 Despite this, questions about adverse 
effects and long term effects of mandatory food fortifica-
tion remain unanswered, and any change in diet must 
be closely monitored.
What is Europe waiting for? A common argument 
is that introducing mandatory fortification to reach a 
relatively small group (women getting pregnant) is not 
a good enough reason to intervene at population level. 
If fortification would also reduce the burden of major 
disorders such as cardiovascular diseases and dementia 
the case might be different. The risks of these disorders 
increase with high plasma concentrations of homo-
cysteine, and folic acid supplementation can reduce 
these concentrations in humans.13 However, definitive 
evidence (such as data from randomised controlled 
trials) of a protective effect of folic acid on these two 
diseases has yet to be found. In theory, any clinical 
improvement could have a long latency period, which 
could make it difficult or impossible to detect even in a 
large randomised controlled trial.
So, if this is the kind of evidence that Europe is wait-
ing for mandatory fortification with folic acid may 
never happen. If this is the case, we will lose the chance 
of decreasing the burden of 4500 neural tube defects 
that occur each year in the European Union alone, not 
to mention the effect on cleft lip with or without cleft 
palate shown by Wilcox and colleagues.
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EDITORIALS
housing and health
Heating improvements may hold most promise for developing healthy  
housing policy
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It has been known for centuries that housing and 
health are inextricably linked. However, most of the 
evidence so far comprises cross sectional studies, 
which can only assess the relation between housing 
and health outcomes rather than provide convinc-
ing evidence that better housing improves health. A 
systematic review of intervention studies (carried out 
in 2001) found that housing improvement may lead 
to small improvements in self reported physical and 
mental health and reductions in some symptoms, but 
adverse effects on health are also possible.1 However, 
the evidence is patchy and robust study designs are 
rare. Of the 18 studies identified in the review, six 
were prospective controlled studies and only one was 
a randomised controlled trial.1
In this week’s BMJ, Howden-Chapman and col-
leagues report a large randomised controlled trial 
from New Zealand assessing whether insulating older 
houses increases indoor temperatures and improves 
occupants’ health and wellbeing.2 The relevance of 
such studies to decision making in public health is 
emphasised in the UK government’s Wanless report, 
which examined the cost effectiveness of taking action 
to improve the health of the whole population and 
to reduce health inequalities.3 The report highlighted 
the almost complete lack of an evidence base for the 
effectiveness and cost effectiveness of public health 
and social interventions. The report also identified the 
need to collect better evidence of the effects of inter-
ventions in the housing sector.
The trial by Howden-Chapman and colleagues 
directly addresses this need. Their study included a cost-
benefit analysis.4 The findings suggest that improving 
the indoor environment may lead to improved self rated 
health (adjusted odds ratio 0.50, 95% confidence inter-
val 0.38 to 0.68), fewer visits to a general practitioner 
(0.73, 0.62 to 0.87), fewer days off work (0.62, 0.46 to 
0.83), and fewer days off school (0.49, 0.31 to 0.80).
In addition to the use of a randomised controlled 
trial design, the strengths of the study include retention 
of more than 75% of the original participants and a 
large final sample size (>3000). This in a field in which 
studies are small (rarely more than 200 participants) 
and retention is rarely more than 50%, if reported at 
all.1 Funding, personal commitment, and expertise are 
likely to explain much of this study’s success, but the 
research team also ensured the commitment of the 
housing agencies that delivered the intervention.5
The lack of consistent health impacts detected in 
previous prospective controlled studies may partly 
be explained by variation in the actual intervention 
delivered and the varying potential to benefit from the 
investment. In the New Zealand trial, not everyone in 
the intervention group received the full intervention 
package.2 5 However, area based programmes may 
deliver improvements regardless of individual need 
at baseline. In one recent controlled non-randomised 
study of housing led neighbourhood regeneration, 
about two thirds of residents reported no housing 
problems at baseline, so limiting the potential to 
improve conditions.6 The small sample sizes in previ-
ous studies often preclude further analysis of subgroup 
effects according to the extent of improvements. The 
New Zealand trial, however, may be large enough to 
allow investigation of a dose-response effect, taking 
into account the range of improvements delivered. 
Heating and energy efficiency measures can improve 
the indoor environment and also alleviate fuel pov-
erty (when a household spends more than 10% of its 
income on fuel). The combination of greater warmth 
and reduced household expenditure may be a key 
mechanism through which health effects occur. Previous 
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Early last week, the Office of Fair Trading (OFT) pub-
lished its report on the Pharmaceutical Price Regu-
lation Scheme,1 a uniquely British mechanism for 
determining the prices the National Health Service 
pays for brand name drugs (currently costing around 
£8bn (€12bn; $15.6bn) a year). For 18 months the 
enquiry team had analysed the scheme, heard evi-
dence, looked at arrangements in other countries, 
and modelled alternatives in an NHS context. Early 
on Tuesday 20 February it delivered its verdict: the 
scheme was no longer fit for purpose and needed to 
change.
The Pharmaceutical Price Regulation Scheme (for-
merly the Voluntary Price Regulation Scheme) has 
been running since 1956. It is a voluntary arrange-
ment between the Department of Health and indi-
vidual drug companies, which determines the prices 
companies can charge the NHS for their drugs.2 The 
scheme has helped keep drug companies based in the 
United Kingdom in good stead since its inception. 
The question that now arises is to what extent the 
scheme serves the purposes of industry rather than 
the interests of patients. This question has been raised 
in at least two parliamentary health select committee 
enquiries in the past 13 years,3 4 but this is the first 
time that a detailed and specific “public” investiga-
tion has been undertaken. The enquiry team has had 
sufficient resources, expertise, and access to otherwise 
confidential material to do the job thoroughly. 
Moreover, the team has published the results in a 
detailed yet accessible manner. 
The purposes of the scheme are clearly set out in 
the agreement of November 2004 (agreements are 
negotiated every five years; the current arrangement 
came into force in January 2005 and is due to end in 
2010).2 From the start, it is clear that the goals of the 
scheme are compromised as they present an insur-
mountable conflict—the scheme is tasked to secure the 
provision of drugs for the NHS at “reasonable prices” 
while simultaneously determining prices that are high 
enough to “sponsor” (more recently called “promote”) 
the wellbeing of UK based companies. Interestingly, 
this has always been the way in which UK govern-
ment worked to ensure that UK manufacturers were 
competitive in an international market.
The workings of the scheme are simple: each year 
companies give the Department of Health details of 
their historic capital (the monies they have tied up in 
plant, machinery, factories, raw materials, etc). After 
taking into account allowances for costs on research 
and development, promotion, and information, the 
department uses a formula to determine the total 
amount the company can charge the NHS (“return 
on capital”) for all of its products (its basket of drugs). 
To reach the permitted return, companies can price 
their drugs high at the time of launch. Moreover, if the 
return on capital is not reached each year the company 
can raise the prices of other drugs in its basket. Con-
versely, if the permitted return is exceeded, the com-
pany is required to reimburse the excess to the NHS 
(“in reality the reimbursements are negligible”1).
The strands of the scheme are such that many of 
the outcomes run counter to the interests of the NHS. 
High prices at launch are essentially inevitable, drugs 
are developed (and rewarded) that do not necessarily 
offer clinical advantage, and the industry alone deter-
mines prices according to what they believe to be their 
product’s value. Moreover, as the prices have been 
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studies indicate that warmer and less humid living 
conditions may improve health, but they also sug-
gest that the health benefits disappear if housing costs 
increase.1 
Several studies assessing the impact on health of heat-
ing improvements are now near completion, including 
a large quasi-experimental evaluation of the Scottish 
Executive’s central heating programme7 These and the 
New Zealand study suggest that heating improvements 
may hold most promise for the development of an evi-
dence base to inform healthy housing policy.
This new trial emphasises the benefits of investing 
in housing, which are not limited to health, as reduc-
tions in work and school absences were also seen. This 
evidence and emerging evidence from other housing 
studies should inform policies linking housing invest-
ment to impacts on health.
1	 	 Thomson	H,	Petticrew	M,	Morrison	D.	Health	effects	of	housing	
improvement:	systematic	review	of	intervention	studies.	BMJ	
2001;323:187-90.
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10.1136/bmj.39070.573032.80.
3	 	 Wanless	D.	Securing good health for the whole population.	London:	
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Regulation of doctors
UK government white paper puts patient safety at the heart of medical practice
On 21 February 2007, the government published its 
white paper Trust, assurance and safety–the regulation of 
health professionals in the 21st century,1 which sets a frame-
work to assure the safety of patients and quality of care. 
The paper considers the English chief medical officer 
Sir Liam Donaldson’s review of medical regulation, 
Good Doctors, Safer Patients2; the Department of Health’s 
report, Regulation of the Non-medical Healthcare Professions3; 
and subsequent consultations with professionals and lay 
people.
The main areas covered by the white paper are how 
to assure the safety of patients in situations where a 
doctor’s performance or conduct pose a risk, the intro-
duction of an effective system of revalidation, and modi-
fications to the role and function of the General Medical 
Council (GMC). 
Patient safety is central to the proposals. At local level 
the value of attempts to ensure quality in the current 
National Health Service is recognised. In the current sys-
tem poor medical performance is dealt with separately 
by the employer (NHS) and the regulator (GMC). This 
may result in a “regulatory gap,” whereby a doctor may 
be providing care that does not inspire the confidence 
of his or her colleagues and employer but his or her 
performance is not so poor that referral to the GMC is 
indicated. Under the new proposals, “GMC affiliates” 
(senior clinicians) are supposed to bridge this gap by 
providing guidance to employers on local investiga-
tions, and to enter “recorded concerns” against a doc-
tor’s GMC registration. This novel idea, probably too 
expensive as a local solution, will be piloted in England 
at regional level.
At national level two key changes are proposed. The 
first is a standard of proof for adjudicating on concerns 
about a doctor’s fitness to practise. The previous crimi-
nal standard of proof—beyond reasonable doubt—now 
changes to the civil standard—the balance of probabil-
ity. This change was proposed by Dame Janet Smith 
in the fifth Shipman report.4 The civil standard will be 
flexibly applied using a sliding scale, with serious cases 
needing evidence at the level of the criminal standard. 
Sliding scales, used by other healthcare regulators and 
the Financial Services Authority, have a credible track 
record.5 However, where a doctor’s reputation is at stake 
some doctors may feel their human rights are being 
violated. Also, it is the role of those adjudicating to judge 
the facts against a standard, and there is a theoretical risk 
that in setting the standard the process of judgment has 
already started before the facts are heard. The second 
change is the introduction of an independent panel that 
will adjudicate cases instead of the GMC and separate 
the role of investigation from judgment.
Against these local and national changes is a firm 
commitment that doctors with performance and health 
436	 	 	 BMJ | 3 MarCh 2007 | VoluMe 334
negotiated by the Department of Health on behalf of 
ministers, it is essentially impossible for government 
to argue that prices are too high. 
Furthermore, there is a real risk that the work of 
bodies such as the National Institute for Health and 
Clinical Excellence (NICE) and the Scottish Medicines 
Consortium, at a national level, and the many drugs 
and therapeutics committees at a local level is under-
mined if money saved is centrally reimbursed in a 
secret deal. Finally, the system no longer appears to 
be sustainable as an organ of government because of 
its inherently conflicting goals and the level of secrecy 
surrounding decision making and outcomes.
The proposals in the OFT report are persuasive. 
Broadly, under a new Pharmaceutical Price Regulation 
Scheme drug prices would be negotiated at launch for 
each drug individually by (ultimately) an independ-
ent commission using robust evidence of the product’s 
perceived clinical value. Representatives of NICE and 
the Scottish Medicines Consortium would be involved 
in determining the price, and presumably if they have 
agreed on its clinical value then the product would be 
available to the NHS immediately after launch (an end 
to “NICE blight”). Finally, any notion of reimburse-
ment or sponsorship would be lost.
Industry will not like these changes. Because the 
fine details for determining perceived clinical value 
are not yet spelled out, companies may be concerned 
that prices could be forced down. They may worry 
that the stability of financial returns will no longer 
be guaranteed, which would pose difficulties in long 
term investment. Until now they have shared the risk 
of drug development with the NHS (if things went 
wrong they could expect reimbursement); under the 
new scheme they would be alone. 
The OFT deserves congratulations for its enquiry 
into the Pharmaceutical Price Regulation Scheme 
and for the recommendations made. The old system 
is arcane and archaic and has to change, and the OFT 
has provided a sound basis for debate and offers an 
appealing alternative. The mystery is that the system 
was not changed years ago.
1	 	 The	Pharmaceutical	Price	Regulation	Scheme:	an	OFT	market	
study.	2007.	www.oft.gov.uk/NR/rdonlyres/7C7A7CC1-F320-
4978-AC64-F67F9AB67B6C/0/oft885.pdf.
2	 	 Department	of	Health	and	the	Association	of	the	British	
Pharmaceutical	Industry.	Pharmaceutical Price Regulation Scheme, 
2004.	www.dh.gov.uk/pprs.
3	 	 House	of	Commons	Health	Select	Committee.	Enquiry into priority 
setting in the NHS: the NHS drugs budget 1993/4.	London:	Stationery	
Office.
4	 	 House	of	Commons	Health	Select	Committee.	Enquiry into the 
influence of the pharmaceutical industry.	Fourth	Report	of	Session	
2004-2005.	London:	Stationery	Office.	www.publications.
parliament.uk/pa/cm200405/cmselect/cmhealth/42/4204.htm.
EDITORIALS
problems will be supported, and that options for reha-
bilitation and retraining will be made available. This is 
to be welcomed but will require a change in culture from 
both the profession and the public to avoid defensive 
practice and a climate of fear.
Doctors accept that revalidation is needed, and half of 
patients think that it already happens. The chief medi-
cal officer’s previously proposed two tier approach of 
relicensure (to enable doctors to remain registered to 
practise) and specialist recertification (to maintain the 
specialist and general practice registers) is endorsed.6
The new system of relicensure will be based on the 
generic standards in Good Medical Practice,7 will involve 
an annual appraisal, which will now contain a summa-
tive element, and any concerns raised by the medical 
director or GMC affiliate will need to be resolved. A 
360º feedback tool (to give feedback on performance 
from several sources) will be piloted to support the 
process. Care will be needed to ensure that the valued 
developmental aspect of appraisal is not lost and that 
new 360º feedback tools have a positive effect on clini-
cians’ practices.8
Specialist recertification, the responsibility of the medi-
cal royal colleges, will be a comprehensive assessment 
against the standards that apply to the particular medical 
college. Information required may include clinical audit, 
simulator tests, knowledge tests, patient feedback, obser-
vation of practice, and continuing professional develop-
ment activities. Standards will need to be set, agreed 
with stakeholders, and tested by each specialty.
Clarity is essential for individual practitioners as to 
what information is required for both relicensure and 
recertification. In terms of how the process might work 
in practice, doctors have been shown to prefer simple 
systems that have a clear structure, with support for 
individuals.9
The changes to the GMC are fewer than were ini-
tially proposed. Members will now be chosen by an 
appointment commission, with equal numbers of lay 
and medical members being appointed. The GMC 
will be accountable to parliament, but independent 
from government. Crucially, the GMC’s international 
reputation and expertise in undergraduate education is 
recognised and their proposed model of undergraduate, 
postgraduate, and continuing professional development 
boards is accepted.
This white paper sets patient safety at the heart of 
medical practice. Medical regulation has evolved. The 
professionally led regulation of the 1990s now gives way 
to partnership regulation with our patients and the NHS. 
Operational details need to be determined, particularly 
in Scotland, Wales and Northern Ireland, and many 
will require legislation. The challenge now is to work 
with our colleagues, professional groups, and patients 
to deliver a fair regulatory system that can inspire the 
confidence of all.
1	 	 Secretary	of	State	for	Health.	Trust, assurance and safety—the regulation 
of health professionals in the 21st century.	London:	Stationery	Office,	
2007.
2	 	 Chief	Medical	Officer.	Good doctors, safer patients.	London:	Department	
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Management of breast cancer in women  
with BRcA gene mutation
Breast conservation surgery is safe in selected women when  
combined with adjuvant therapy
Germline mutation may account for up to 10% of breast 
cancers.1 Known mutations in the BRCA1 and BRCA2 
genes are responsible for about 45% of breast cancer 
susceptibility syndromes (genetic abnormalities that 
put patients at high risk of developing breast cancer), 
which are inherited in an autosomal dominant pattern.1 
Variants of the BRCA genes increase the overall risk of 
developing breast cancer and are also associated with 
a high risk of early onset breast cancer.
Once BRCA1 or BRCA2 mutation has been con-
firmed, preventative strategies include bilateral pro-
phylactic mastectomy and intensive screening with 
possible hormonal manipulation. Although prevention 
of primary breast cancer with mastectomy reduces the 
risk of breast cancer by 89.5-100%, understandably it 
is unacceptable to many women.2 3 This is because 
it has a negative impact on self image, it involves major 
surgery, it cannot remove all risk, and patients may 
find it hard to accept its theoretical benefit as not all 
carriers develop breast cancer.
For women with breast cancer unrelated to BRCA 
(“sporadic breast cancer”), breast conserving surgery 
combined with radiotherapy is used where appropriate 
and is now regarded as the standard of care.4 Con-
ceptually, breast conserving surgery may seem unwise 
in women with BRCA related breast cancer because 
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of the potential risk of in-breast tumour recurrence. 
After more than a decade of research the optimal 
local treatment for these women remains a source 
of contention.
The largest series to date examined breast conser- 
ving surgery in 160 women with BRCA mutation and 
found a 10 year in-breast tumour recurrence of 12%.5 
In women with sporadic breast cancer, the cumulative 
10 year in-breast tumour recurrence in five national 
surgical adjuvant breast and bowel project trials was 
8.7%.6 The risk in women with BRCA mutation 
is therefore slightly higher than in women without, 
though it seems to be acceptable, as previous trials in 
women with sporadic breast cancer have reported in-
breast tumour recurrence between 10% and 15% at 10 
years. Furthermore, when women with BRCA related 
breast cancer were compared retrospectively with age 
matched controls with sporadic breast cancer, no sig-
nificant difference was found in the risk of in-breast 
tumour recurrence, provided the women with BRCA 
related breast cancer had undergone bilateral prophy-
lactic oophorectomy.5 However, women with BRCA 
mutation who did not have prophylactic oophorectomy 
had twice the rate of in-breast tumour recurrence 
relative to controls.5 Although the risk of ovarian 
cancer in women with BRCA mutation is much lower 
than the risk of breast cancer, bilateral prophylactic 
oophorectomy reduces the risk of a new breast 
cancer as a result of hormone deprivation.7 Prophylactic 
oophorectomy reduces the risk of breast cancer by 
about 70% in women with BRCA mutation, and short 
term hormone replacement therapy after surgery does 
not seem to negate this protective effect.8
Apart from an increased risk of in-breast tumour 
recurrence, women with BRCA mutation who have 
breast conserving surgery also have a greater incidence 
of new primary tumours in the contralateral breast than 
women with sporadic breast cancer (42% v 9% at 12 
years).9 Bilateral prophylactic oophorectomy combined 
with tamoxifen reduces the risk of contralateral breast 
cancer by as much as 50% in women with BRCA muta-
tion, supporting hormonal intervention.5
 Tamoxifen reduces the risk of in-breast tumour 
recurrence in these women, and this protective effect 
increases with the duration of treatment (up to four 
years).10
The only specific BRCA chemoprevention stud-
ies have been small single centre trials. Several ran-
domised controlled trials have assessed tamoxifen 
as a chemoprevention strategy in high risk patients, 
however, and post randomisation analysis of those 
with BRCA mutation has shown tamoxifen to be up 
to 50% effective in preventing breast cancer in these 
patients.11 In addition, tamoxifen can reduce the inci-
dence of a second primary cancer by 50% in women 
with BRCA mutation.11 So what does all this mean 
for patients and the clinicians advising them? Overall, 
the evidence indicates that breast conservation is safe 
in selected women with BRCA related cancers when 
combined with optimal adjuvant therapy.4 Recent data 
show that women who have breast conserving surgery 
rather than mastectomy for breast cancer score higher 
on quality of life measures, and these findings are prob-
ably applicable to women with BRCA mutation.12 
However, women with BRCA related breast cancer 
should be informed of the relative risks and benefits 
of bilateral prophylactic mastectomy compared with 
breast conservation so they can be supported in 
making their own decisions.
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